SCHEMBL1869119

SCHEMBL1869119

CCCCN1C(=O)CCC1C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
POLB P06746 1/20 0.48
CHRM2 P08172 3/20 0.46
CHRM4 P08173 3/20 0.46
CHRM5 P08912 3/20 0.46
CHRM1 P11229 3/20 0.46
CHRM3 P20309 3/20 0.46
TP53 P04637 2/20 0.46
GAA P10253 2/20 0.46
ALDH1A1 P00352 1/20 0.43
ABL1 P00519 2/20 0.42
RIN1 Q13671 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
MDM2 Q00987 1/20 0.42
PTGER4 P35408 7/20 0.39
PTGER3 P43115 6/20 0.39
PTGER2 P43116 5/20 0.39
PER2 O15055 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635213 0.94 CHRM2 (0.45) MEN1KMT2APOLBCHRM2CHRM4
SCHEMBL665342 0.93 PTGER4 (0.46) MEN1KMT2APOLBCHRM2CHRM4
SCHEMBL664674 0.93 PTGER4 (0.46) MEN1KMT2APOLBCHRM2CHRM4
SCHEMBL4329362 0.93 PTGER4 (0.46) MEN1KMT2APOLBCHRM2CHRM4
SCHEMBL4588711 0.93 PTGER4 (0.46) MEN1KMT2APOLBCHRM2CHRM4
SCHEMBL664648 0.93 PTGER4 (0.46) MEN1KMT2APOLBCHRM2CHRM4
SCHEMBL30697351 0.93 PTGER4 (0.46) MEN1KMT2APOLBCHRM2CHRM4
SCHEMBL4588206 0.93 PTGER4 (0.46) MEN1KMT2APOLBCHRM2CHRM4
SCHEMBL4588299 0.93 PTGER4 (0.46) MEN1KMT2APOLBCHRM2CHRM4
Methane SCHEMBL4593708 0.93 CHRM2 (0.44) MEN1KMT2APOLBCHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116422367-B Zirconium-silicon molecular sieve encapsulated platinum sub-nanoparticle catalyst and preparation method and application thereof 天津师范大学 2025-01-28 CN claimed
CN-117897439-A Method for screening solvent for extraction of polyvinyl chloride, method for recovering waste material, and recovered polyvinyl chloride and composition 株式会社LG化学 2024-04-16 CN claimed
CN-116422367-A Zirconium-silicon molecular sieve encapsulated platinum sub-nanoparticle catalyst and preparation method and application thereof 天津师范大学 2023-07-14 CN claimed
CN-116422367-B Zirconium-silicon molecular sieve encapsulated platinum sub-nanoparticle catalyst and preparation method and application thereof 天津师范大学 2025-01-28 CN disclosed
CN-116550362-B FeNi@NC bimetallic catalyst and preparation method and application thereof 浙江工业大学 2024-12-10 CN disclosed
CN-115709077-B Method for preparing 5-methyl-N-substituted pyrrolidone compound 中国科学院广州能源研究所 2024-06-28 CN disclosed
CN-117897439-A Method for screening solvent for extraction of polyvinyl chloride, method for recovering waste material, and recovered polyvinyl chloride and composition 株式会社LG化学 2024-04-16 CN disclosed
CN-117897440-A Method for screening solvent for extraction of polyvinyl chloride, method for recycling waste material, recycled polyvinyl chloride and composition 株式会社LG化学 2024-04-16 CN disclosed
CN-116550362-A FeNi@NC bimetallic catalyst and preparation method and application thereof 浙江工业大学 2023-08-08 CN disclosed
CN-116422367-A Zirconium-silicon molecular sieve encapsulated platinum sub-nanoparticle catalyst and preparation method and application thereof 天津师范大学 2023-07-14 CN disclosed
US-20230167545-A1 STABILIZATION OF CARBON DEPOSITION PRECURSORS LIKE C2H2 LAM RESEARCH CORPORATION 2023-06-01 US disclosed
US-8026273-B2 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2011-09-27 US disclosed
WO-2011054387-A1 COSMETIC COMPOSITIONS COMPRISING AN ESTER DERIVED FROM 4-CARBOXY-2-PYRROLIDINONE AND A MEROCYANIN SCREENING AGENT; USE OF SAID DERIVATIVE AS A SOLVENT FOR A MEROCYANIN SCREENING AGENT L'OREAL (FR) 2011-05-12 WO disclosed
US-20100143276-A1 Ester solvents derived from 4-carboxy-2-pyrrolidinone formulated into UV-screening cosmetic compositions L'OREAL (FR) 2010-06-10 US disclosed
US-20100113388-A1 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
US-7683094-B2 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2010-03-23 US disclosed
US-20090042885-A1 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2009-02-12 US disclosed
EP-2004744-A1 COMPOSITION INCLUDING MULTIPLE FUNCTIONALIZED POLYMERS Bridgestone Corporation (JP) 2008-12-24 EP disclosed
US-7402605-B2 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-07-22 US disclosed
WO-2007120797-A1 COMPOSITION INCLUDING MULTIPLE FUNCTIONALIZED POLYMERS BRIDGESTONE CORPORATION (JP) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042885-A1 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT PTGER2, PTGIS, HPGDS MEN1 3441/4885KMT2A 4644/4885POLB 2542/4885
US-20100143276-A1 Ester solvents derived from 4-carboxy-2-pyrrolidinone formulated into UV-screening cosmetic compositions FASN, ALOX12, PAH MEN1 2738/4885KMT2A 2116/4885POLB 436/4885
US-20100113388-A1 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT PTGER2, PTGIS, HPGDS MEN1 3441/4885KMT2A 4644/4885POLB 2542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.